Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

17 May 2017 07:00

RNS Number : 3487F
Ideagen PLC
17 May 2017
 

This announcement contains inside information.

 

 

17 May 2017

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2017 ahead of the announcement of its full year results on or around 18 July 2017.

 

The Board is pleased to report that results to 30 April 2017 are expected to be in line with market expectations and that trading was once again robust across all key verticals, with particular success within the Life Sciences, Aviation and Financial sectors. The Group delivered organic revenue growth* of approximately 10 per cent together with further contributions from all four acquisitions made during the year. This represents the Group's eighth consecutive year of revenue and adjusted EBITDA** growth.

 

The Group expects to report revenue of approximately £27.1million, (FY2016: £21.9 million) and adjusted EBITDA** of approximately £7.8 million (FY2016: £6.3 million), both having increased by approximately 24%, and a significant increase in adjusted EPS***, which continues to be an important financial metric for the Group.

 

The Board is confident that the transition from a traditional 'perpetual licence' business model to a 'subscription licence' model is well underway, as evidenced by a significant increase in the run-rate of recurring revenues. This has been driven primarily by the success of Coruson, our SaaS based enterprise Risk and Safety Management solution which is allowing the Group to win larger contracts and grow high visibility, subscription-based revenue. 

 

Cash generation was extremely strong at the end of the financial year and accordingly net cash at 30 April 2017 was significantly ahead of market forecasts at £4.2 million (31 October 2016: £4.8 million), even after paying £4.6 million of consideration for the acquisitions of IPI Solutions and Gael (deferred) and £0.3 million in dividends. The Board expects to report that cash generated by operations will be in excess of 100% of adjusted EBITDA**.

 

 

David Hornsby, Chief Executive, commented: "We are pleased to report that the Group has continued to perform well in delivering another year of high quality earnings growth underpinned by strong cash generation. We have also made four important acquisitions which have provided scale, product capability and recurring revenues. We continue to grow organically and to increase the percentage of our revenues derived from recurring business. The Group has significant contracted work in progress and a strong pipeline of new business opportunities which provides the Board with confidence for the current year and beyond."

 

* FY2016 comparator prepared on a proforma basis as if these acquisitions had occurred during that year

**Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

***Adjusted diluted earnings per share

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Stuart Andrews/Henrik Persson/James Thompson (Nomad)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in GRC (Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 3,000 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDQLFFDEFXBBK
Date   Source Headline
20th Apr 20221:01 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (HHL)
20th Apr 202212:58 pmGNWForm 8.3 - [Ideagen plc - 19 04 2022] - (CGWL)
20th Apr 202212:54 pmRNSForm 8.3 - Ideagen plc
20th Apr 202212:34 pmRNSForm 8.3 - Ideagen Plc
20th Apr 202212:28 pmRNSForm 8.3 - Ideagen PLC
20th Apr 202211:56 amBUSForm 8.3 - Ideagen Plc
20th Apr 202211:38 amRNSForm 8.5 (EPT/RI)
20th Apr 202211:11 amRNSForm 8 (DD) - Ideagen Plc
20th Apr 202210:52 amGNWForm 8.3 - Ideagen
20th Apr 202210:42 amGNWForm 8.3 - Ideagen Plc
20th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - Ideagen Plc
20th Apr 20229:11 amRNSForm 8.5 (EPT/RI)
19th Apr 20225:44 pmBUSForm 8.3 - Ideagen PLC
19th Apr 20225:28 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20225:19 pmRNSForm 8.3 - Ideagen plc
19th Apr 20221:32 pmRNSForm 8.3 - Ideagen PLC
19th Apr 20227:00 amRNSResponse to Cinven Statement
14th Apr 20225:26 pmRNSPossible Offer for Ideagen PLC
13th Apr 202212:00 pmRNSIssue of shares, Director/PDMR Shareholding & TVR
8th Apr 202212:30 pmRNSExercise of Options and Total Voting Rights
1st Apr 20227:00 amRNSTotal Voting Rights
25th Mar 20226:00 pmRNSDirector/PDMR Shareholding
14th Mar 20227:00 amRNSIssue of Equity and TVR
1st Mar 20222:35 pmRNSDirector/PDMR Shareholding
1st Mar 20222:30 pmRNSTotal Voting Rights
11th Feb 20225:45 pmRNSIssue of Shares under SIP and TVR
11th Feb 202211:01 amRNSHolding(s) in Company
9th Feb 20227:01 amRNSAcquisition of MailManager
9th Feb 20227:00 amRNSChange of Adviser
1st Feb 20228:30 amRNSTotal Voting Rights
13th Jan 20227:01 amRNSGrant of awards under the Ideagen LTIP
13th Jan 20227:00 amRNSUnaudited Interim Results
12th Jan 202212:02 pmRNSIssue of Shares Under SIP and Total Voting Rights
4th Jan 20222:45 pmRNSTotal Voting Rights
14th Dec 20214:30 pmRNSIssue of Shares Under SIP and Total Voting Rights
13th Dec 20216:00 pmRNSHolding(s) in Company
9th Dec 20219:05 amRNSSecond Price Monitoring Extn
9th Dec 20219:00 amRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20214:50 pmRNSRetail Offer by PrimaryBid
8th Dec 20214:49 pmRNSProposed Placing of Ordinary Shares
1st Dec 20214:15 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSCapital Markets Day
15th Nov 20217:00 amRNSHalf Year Trading Update and Acquisition
12th Nov 20214:46 pmRNSIssue of new shares under the SIP and TVR
9th Nov 20217:00 amRNSAcquisition of CompliSpace
1st Nov 202111:52 amRNSTotal Voting Rights
28th Oct 20215:30 pmRNSResult of AGM
27th Oct 20217:00 amRNSAcquisitions of Audit Analytics and Ai XPRT
22nd Oct 20217:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.